IRCT201407111772N15已完成3 期
Premediacation with single dose of Acetazolamid for the control of referred shoulder pain after laparoscopic cholecystectomy
Tabriz university of medical science/ Vice chancellor of reseach0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 years 至 60 years（—）
- 性别
- All
入选标准
- •all patients undergoing laparoscopic cholecystectomy in rang of 30-60 years old.
- •Exclusion criteria:1- addiction 2-psychopathic patients 3- patient avoidance 4-previous pain full disease 5-Sensitivity to sulfonamides 6- renal failer 7-COPD and lung disease8-pregnancy 9-hematologic disorder 10- previous acidosis 11- renal implantation 12-exitance of electrolyte imbalance 13- previous Lithium consumption 14- CNS disorder 15-Hepatic disorder16-use of other diuretics 17-previous shoulder pathology 18- previous muscle disease 19- hypoglycemia
排除标准
- 未提供
研究者
相似试验
招募中
3 期
To evaluate the effect of acetazolamide in the prevention of intraventricular hemorrhage in preterm newbornsIntracranial hemorrhage in preterm newborns.Unspecified intraventricular (nontraumatic) hemorrhage of newbornP52.3IRCT20210607051507N3Tehran University of Medical Sciences132
已完成
2 期
Effect of acetazolamide on the prevention of cerebrospinal fluid leakage after spinal surgeryDura damage.Cerebrospinal fluid leak from spinal punctureIRCT201501178612N2Pharmaceutical care department-Shariati Hospital70
招募中
3 期
Evaluating the effect of Acetazolamide on the prevention of post-operative Acute Kidney Injury following Coronary Artery Bypass Grafting surgeryAcute kidney injuryIRCT20151227025726N21Shahid Beheshti University of Medical Sciences70
已完成
3 期
Factors affecting the outcome of Lumbosacral Spinal SurgeryCondition 1: Tethered cord- split cord malformation. Condition 2: Lipomyelomeningocele.Disorder of brain, unspecifiedBenign lipomatous neoplasm, unspecifiedIRCT2012100611023N1Tehran University of Medical Sciences144
招募中
不适用
Randomized controlled trial of Acetazolamide to treat schizophreniaCTRI/2021/02/031415Stanley Medical Research Institute